A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogenicity by facilitating helper T-cell responses to a covalently linked carrier protein

Vaccine

Volumn 17, Issue 19, 1999, Pages 2392-2399

  Oscherwitz, Jon ^a   Zeigler, Mary E ^a   Gribbin, Thomas E ^a,b   Cease, Kemp B ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antibodies; B lymphocytes; Tandem epitopes

Indexed keywords

CARRIER PROTEIN; EPITOPE; HAPTEN; VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; COVALENT BOND; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TANDEM REPEAT;

EID: 0033553598     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00030-4     Document Type: Article

References (47)

1. Dintzis R.Z., Okajima M., Middleton M.H., Greene G., Dintzis H.M. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J. Immunol. 143:1989;1239-1244.
2. Klaus G.G.B., Cross A.M. The influence of epitope density on the immunological properties of hapten-protein conjugates. I. Characteristics of the immune response to hapten-coupled albumen with varying epitope density. Cell. Immun. 14:1974;226-241.
3. Rubin B. Studies on the induction of antibody synthesis against sulfanilic acid in rabbits I. Effect of the number of hapten molecules introduced in homologous protein on antibody synthesis against the hapten and the new antigenic determinants. Eur. J. Immunol. 2:1972;5-11.
4. Larralde C., Janof P. The effects of the DNP:HSA molar ratio on the quantity and the affinity of rat anti-DNP antibodies in the primary response. Immunochemistry. 9:1972;1209-1219.
5. Quijada L., Kim Y.T., Siskind G.W., Ovary Z. Immunogenicity of lowly and highly derivatized dinitrophenyl-bovine g-globulin in different strains of guinea pigs. J. Immunol. 113:1974;1296-1301.
6. Zheng B., Graham F.L., Johnson D.C., Hanke T., McDermott M.R., Prevec L. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine. 11:1993;1191-1198.
7. Broekhuijsen M.P., Van Rijn J.M.M., Blom A.J.M., Pouwels P.H., Enger-Valk B.E., Brown F., Francis M.J. Fusion proteins with multiple copies of the major antigenic determinant of foot-and-mouth disease virus protect both the natural host and laboratory animals. J. Gen. Virol. 68:1987;3137-3143.
8. Broekhuijsen M.P., Blom T., van Rijn J., Pouwels P.H., Klasen E.A., Fasbender M.J., Enger-Valk B.E. Synthesis of fusion proteins with multiple copies of an antigenic determinant of foot-and-mouth disease virus. Gene. 49:1986;189-197.
9. Anjam Khan C.M., Villarreal-Ramos B., Pierce R.J., Demarco de Hormaeche R., McNeill H., Ali T., Chatfield S., Capron A., Dougan G., Hormaeche C.E. Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma Mansoni peptide 115-131 of the P22 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live Aro-attenuated vaccine strain of Salmonella. J. Immunol. 153:1994;5634-5642.
10. Tam J.P., Clavijo P., Lu Y.-A., Nussenzweig V., Nussenzweig R., Zavala F. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J. Exp. Med. 171:1990;299-306.
11. Lowell G.H., Ripley Ballou W., Smith L.F., Wirtz R.A., Zollinger W.D., Hockmeyer W.T. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science. 240:1988;800-802.
12. Lo-Man R., Martineau P., Hofnung M., Leclerc C. Induction of T-cell responses by chimeric bacterial proteins expressing several copies of a viral T-cell epitope. Eur. J. Immunol. 23:1993;2998-3002.
13. Lowenadler B., Svennerholm A.-M., Gidlund M., Holmgren E., Krook K., Svanholm C., Ulff S., Josephson S. Enhanced immunogenicity of recombinant peptide fusions containing multiple copies of a heterologous T helper epitope. Eur. J. Immunol. 20:1990;1541-1545.
14. Oscherwitz J., Zeigler M.E., Lohff C.J., Gribbin T.E., Cease K.B. The enhanced immunogenicity of a recombinant immunogen containing a tandemly repeated HIV-1 T helper epitope is an intrinsic immunological property unrelated to epitope dose. Vaccine Res. 6:1997;15-25.
15. Borras-Cuesta F., Fedon Y., Petit-Camurdan A. Enhancement of peptide immunogenicity by linear polymerization. Eur. J. Immunol. 18:1988;199-202.
16. Del Giudice G., Cooper J.A., Merino J., Verdini A.S., Pessi A., Togna A.R., Engers H.D., Corradin G., Lambert P.H. The antibody response in mice to carrier-free synthetic polymers of plasmodium falciparum circumsporozoite repetitive epitope is I-A-restricted: possible implications for malaria vaccines. J. Immunol. 137(9):1986;2952-2955.
17. Ahlers J.D., Dunlop N., Pendelton C.D., Newman M., Nara P.L., Berzofsky J.A. Candidate HIV type 1 multideterminant cluster peptide-p18MN vaccine constructs elicit type 1 helper T-cells, cytotoxic T-cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res. Hum. Retroviruses. 12:1996;259-272.
18. Human retroviruses and AIDS. 1995;Theoretical Biology and Biophysics, Los Alamos.
19. Taylor W.H., Hagerman P.J. A general method for cloning DNA fragments in multiple copies. Gene. 53:1987;139-144.
20. Kim S.C., Szybalski W. Amplification of cloned DNA as tandem multimers using BspM I-generated asymmetric cohesive ends. Gene. 71:1988;1-8.
21. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA. 74:1977;5463-5467.
22. Esparza I., Kissel T. Parameters affecting the immunogenicity of microencapsulated tetanus toxoid. Vaccine. 10:1992;714-720.
23. Bottomly K., Janeway C.A. Antigen presentation by B-cells. Nature. 337:1989;24.
24. Boehncke W.-H., Takeshita T., Pendleton C.D., Houghten R.A., Sadegh-Nasseri S., Racioppi L., Berzofsky J.A., Germain R.N. The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T-cell recognition. J. Immunol. 150:1993;331-341.
25. Berzofsky J.A. Epitope selection and design of synthetic vaccines: molecular approaches to enhancing immunogenicity and crossreactivity of engineered vaccines. Ann. N. Y. Acad. Sci. 690:1993;256-2641.
26. Pogue R.R., Eron J., Frelinger J.A., Matsui M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl. Acad. Sci. USA. 92:1995;8166-8170.
27. Parkhurst M.R., Salgaller M.L., Southwood S., Robbins P.F., Sette A., Rosenberg S.A., Kawakami Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:1996;2539-2548.
28. Ahlers J.D., Takeshita T., Pendleton C.D., Berzofsky J.A. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc. Natl. Acad. Sci. USA. 94:1997;10856-10861.
29. Fernandez I.M., Golding H., Benaissa-Trouw B.J., de Vos N.M., Harmsen M., Nottet H.S.L.M., Golding B., Puijk W.C., Meloen R.H., Snippe H., Kraaijeveld C.A. Induction of HIV-1 IIIb neutralizing antibodies in BALB/c mice by a chimeric peptide consisting of a T-helper cell epitope of Semliki Forest virus and a B-cell epitope of HIV. Vaccine. 16:1998;1936-1940.
30. Gribbin T.E., Oscherwitz J., Dean-McKinnney T., Cease K.B. Development and efficacy of highly engineered anti-idiotype immunogens. Vaccine Res. 6:1997;101-111.
31. Fontenot J.D., Vancott T.C., Parekh B.S., Pau C.-P., George J.R., Birx D.L., Zolla-Pazner S., Gorny M.K., Gatewood J.M. Presentation of HIV V3 loop epitopes for enhanced antigenicity, immunogenicity and diagnostic potential. AIDS. 9:1995;1121-1129.
32. Fontenot J.D., Tan X., Philips D.M. Structure-based design of peptides that recognize the CD4 binding domain of HIV-1 gp120. AIDS. 12:1998;1413-1418.
33. Thielemans K., Rothbard J.B., Levy S., Levy R. Syngeneic anti-idiotypic immune responses to a B-cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens. J. Exp. Med. 162:1985;19-34.
34. Oscherwitz J, Gotch FM, Cease KB, Berzofsky JA. New insights and approaches regarding B- and T-cell epitopes in HIV vaccine design. AIDS 1999, in press.
35. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:1998;648-659.
36. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., Sodroski J.G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:1998;705-711.
37. Feldmann M. Induction of immunity and tolerance in vitro by hapten protein conjugates. I. The relationship between the degree of hapten conjugation and the immunogenicity of dinitrophenylated polymerized flagellin. J. Exp. Med. 135:1972;735-753.
38. Bystryn J.-C., Siskind W., Uhr J.W. Binding of antigen by immunocytes I. Effect of ligand valence on binding affinity of MOPC 315 cells for DNP conjugates. J. Exp. Med. 137:1973;301-316.
39. Davie J.M., Paul W.E. Receptors on immunocompetent cells. IV. Direct measurement of avidity of cell receptors and cooperative binding of multivalent ligands. J. Exp. Med. 135:1972;643-659.
40. Van der Ploeg J.R., Drijfhout J.W., Feijlbrief M., Bloemhoff W., Welling G.W., Welling-Wester S. Immunological properties of multiple repeats of a linear epitope of herpes simplex virus type 1 glycoprotein D. J. Immunol. Methods. 124:1989;211-217.
41. Sette A., Sidney J., Albertson M., Miles C., Colon S.M., Pedrazzini T., Lamont A.G., Grey H.M. A novel approach to the generation of high affinity class II-binding peptides. J. Immunol. 145:1990;1809-1813.
42. Rock K.L., Benacerraf B.F., Abbas A.K. Antigen presentation by hapten-specific B-lymphocytes. I. Role of surface immunoglobulin receptors. J. Exp. Med. 160:1984;1102-1113.
43. Lanzavechia A. Antigen-specific interaction between T- and B-cells. Nature. 314:1985;537-539.
44. Huchet R., Feldmann M. Studies on antibody affinity in mice. Eur. J. Immunol. 3:1973;49-55.
45. Janeway C.A. Jr., Ron J., Katz M.E. The B-cell is the initiating antigen-presenting cell in peripheral lymph nodes. J. Immunol. 138:1987;1051-1055.
46. Ron Y., Sprent J. T-cell priming in vivo: a major role for B-cells in presenting antigen to T-cells in lymph nodes. J. Immunol. 138:1987;2848-2856.
47. Gershon R.K., Paul W.E. Effect of thymus-derived lymphocytes on amount and affinity of anti-hapten antibody. J. Immunol. 106:1971;872-874.